Company news
Syndax Pharmaceuticals, Inc. news in 2019
Syndax Pharmaceuticals, Inc.'s news releases, calls and decks from 2019, newest first.
Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease
December 9, 2019
Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias
December 8, 2019
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
November 6, 2019
Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
November 5, 2019
Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019
October 30, 2019
Syndax Announces Participation at Four Upcoming Investor Conferences
August 27, 2019
Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update
August 6, 2019
Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019
July 30, 2019
Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias
July 9, 2019
Decks in 2019
- Investor Presentation (December 2019)
Investor deck · 27 slides · Dec 10, 2019
- Investor Presentation (October 2019)
Investor deck · 25 slides · Oct 7, 2019